Voreloxin (BioDeep_00000769820)
代谢物信息卡片
化学式: C18H19N5O4S (401.11576940000003)
中文名称: Voreloxin
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CNC1CN(CC1OC)C2=NC3=C(C=C2)C(=O)C(=CN3C4=NC=CS4)C(=O)O
InChI: InChI=1S/C18H19N5O4S/c1-19-12-8-22(9-13(12)27-2)14-4-3-10-15(24)11(17(25)26)7-23(16(10)21-14)18-20-5-6-28-18/h3-7,12-13,19H,8-9H2,1-2H3,(H,25,26)/t12-,13-/m0/s1
描述信息
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic
C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents
同义名列表
1 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- KEGGdrug: D08024
- PubChem: 9952884
- DrugBank: DB11999
- ChEMBL: CHEMBL68117
- CAS: 960398-99-6
- CAS: 174726-60-4
- CAS: 175414-77-4
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Fangbing Liu, Tristan Knight, Yongwei Su, Holly Edwards, Guan Wang, Yue Wang, Jeffrey W Taub, Hai Lin, Liwei Sun, Yubin Ge. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
Targeted oncology.
2019 06; 14(3):351-364. doi:
10.1007/s11523-019-00638-4. [PMID: 31115744] - Xian-Li Zhao, Chun-Zhi Yu. Vosaroxin induces mitochondrial dysfunction and apoptosis in cervical cancer HeLa cells: Involvement of AMPK/Sirt3/HIF-1 pathway.
Chemico-biological interactions.
2018 Jun; 290(?):57-63. doi:
10.1016/j.cbi.2018.05.011. [PMID: 29800573] - C M Nijenhuis, L Lucas, H Rosing, A D R Huitema, M Mergui-Roelvink, G C Jamieson, J A Fox, D R Mould, J H M Schellens, J H Beijnen. Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II.
Investigational new drugs.
2017 08; 35(4):478-490. doi:
10.1007/s10637-017-0428-1. [PMID: 28138829] - C M Nijenhuis, L Lucas, H Rosing, G Jamieson, J A Fox, J H M Schellens, J H Beijnen. Quantification of vosaroxin and its metabolites N-desmethylvosaroxin and O-desmethylvosaroxin in human plasma and urine using high-performance liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2016 Aug; 1027(?):1-10. doi:
10.1016/j.jchromb.2016.05.016. [PMID: 27236532] - J E Lancet, F Ravandi, R M Ricklis, L D Cripe, H M Kantarjian, F J Giles, A F List, T Chen, R S Allen, J A Fox, G C Michelson, J E Karp. A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia.
Leukemia.
2011 Dec; 25(12):1808-14. doi:
10.1038/leu.2011.157. [PMID: 21760592] - Marc J Evanchik, Darin Allen, Josh C Yoburn, Jeffrey A Silverman, Ute Hoch. Metabolism of (+)-1,4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595), a novel replication-dependent DNA-damaging agent.
Drug metabolism and disposition: the biological fate of chemicals.
2009 Mar; 37(3):594-601. doi:
10.1124/dmd.108.023432. [PMID: 19074528]